[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hand-foot-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hand-foot-syndrome":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100562361","electroacupuncture-combined-with-self-administered-acupressure-for-the-prevention-of-capecitabine-associated-hand-foot-syndrome-100562361",false,"NCT06602167","Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome","Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Sign a written informed consent form;\n2. Male or female ≥ 18 years old;\n3. Patients with gastrointestinal cancer or breast cancer who are diagnosed with cancer by pathology will receive capecitabine treatment for the first time according to the label;\n4. The performance status of the Eastern Cancer Collaboration Group is 0-2;\n5. Palliative or adjuvant chemotherapy with capecitabine (combination or monotherapy, minimum daily total dose of capecitabine 2000 mg\u002Fm\\^2);\n6. Expected lifespan ≥ 3 months;\n7. Laboratory requirements: platelet count ≥ 100 × 10\\^9\u002FL, white blood cell count\\>3.0 × 10\\^9\u002FL, hemoglobin ≥ 10.0 g\u002FdL, normal liver and kidney function;\n8. Adequate contraception.\n\nExclusion Criteria:\n\n1. Previous use of capecitabine or liposome doxorubicin or any other tyrosine kinase inhibitor that may induce HFS (such as sorafenib, sunitinib, and apatinib) for chemotherapy;\n2. The initial dose of capecitabine is less than 800mg\u002Fm\\^2;\n3. Radiation therapy or surgery should be performed within 4 weeks before the start of treatment;\n4. Skin diseases that may interfere with clinical trial results;\n5. Known drug\u002Falcohol abuse;\n6. Pregnant women or lactating patients;\n7. Participate in another clinical trial and the patient has received the investigational drug within the last 30 days prior to the start of treatment (i.e. follow-up in the previous trial was not exclusive);\n8. Known patients who are afraid of electroacupuncture stimulation or allergic to stainless steel needles or any component of capecitabine;\n9. Receive any acupuncture and moxibustion treatment ,there is lymphedema in the area stimulated by acupuncture;\n10. Patients with any chemotherapy- or radiotherapy-related toxicities that have not subsided to grade 2 or lower will be excluded, except for stable sensory neuropathy.\n11. Any unresolved skin toxicity caused by previous chemotherapy or radiotherapy, except for hair loss, will also be grounds for exclusion.",true,"ALL","18 Years","85 Years",{"count":21,"type":22},220,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study hypothesizes that electroacupuncture combined with self-administered acupressure plus doctor-prescribed treatment is effective in preventing Hand-Foot Syndrome (HFS) caused by capecitabine. It aims to explore the effectiveness of this combined approach in preventing HFS in patients with malignant tumors undergoing oral capecitabine treatment. Further exploration of prevention and treatment methods may enhance the quality of life for patients during the treatment process.",[28,29,30,31,32,33],"Capecitabine","Hand-foot Syndrome","Electroacupuncture","Self-administered Acupressure","Breast Cancer","Gastrointestinal Cancers",[35,36,37,38,39,40],"electroacupuncture","capecitabine","self-administered acupressure","Hand-foot syndrome","Breast cancer","Gastrointestinal cancers","RECRUITING","2024-12-09",{"date":44,"type":45},"2024-12-12","ACTUAL",{"date":47,"type":45},"2024-10-08",{"date":49,"type":22},"2027-12-31",{"name":51,"class":52},"Affiliated Hospital of Qinghai University","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":5},"100437653","photobiomodulation-therapy-in-the-management-of-hand-foot-syndrome-and-hand-foot-skin-reaction-100437653","NCT04979078","Photobiomodulation Therapy in the Management of Hand-foot Syndrome and Hand-foot Skin Reaction","Evaluating the Effectiveness of Photobiomodulation Therapy in the Management of Hand-foot Syndrome and Hand-foot Skin Reaction: A Single-arm Trial","DermLight","Inclusion Criteria:\n\n* Diagnosed with cancer of different aetiologies\n* Undergoing chemotherapy or targeted therapy (TKIs)\n* Diagnosed with HFS-HFSR grade 1, 2 or 3 (National Cancer Institute - Common Terminology Criteria for Adverse Events, NCI-CTCAE v5)\n* Age ≥ 18 years\n* Able to comply to the study protocol\n* Able to sign written informed consent\n\nExclusion Criteria:\n\n* Pre-existing skin rash, ulceration or open wound in the treatment area (hand, foot)\n* Known allergy to polyurethane\n* Substance abuse patients or patients with medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results as judged by the investigator\n* Any condition that is unstable or could affect the safety of the patient and their compliance in the study as judged by the investigator",{"count":63,"type":22},40,[25],"Hand-foot syndrome (HFS) is a side effect of chemotherapy. HFS is characterized by redness, swelling, and pain on the palms of the hands and\u002For soles of the feet, which can progress to blistering. Hand-foot skin reaction (HFSR) refers to symptoms affecting the hands and\u002For feet associated with multikinase inhibitors (TKIs). HFS and HFSR are painful complications that can lead to compromised daily activities, sleep-wake disturbance and impaired mobility, eventually decreasing Quality of Life (QoL).\n\nPhotobiomodulation therapy (PBMT) is a non-invasive therapy based on the application of visible and\u002For near-infrared light produced by a laser diode or a light-emitting diode. The scientifically proven biologic effects of PBM are improved wound healing, and a reduction in pain, inflammation, and oedema. The aim of this study is to evaluate the effectiveness of PBMT in the management of HFS and HFSR.",[29,67],"Hand-foot Skin Reaction",[69,70,71,72,38,73,74,75,76],"Dermatology","Oncology","Photobiomodulation","Skin toxicity","Hand-foot skin reaction","Hand-foot skin toxicity","Supportive cancer care","Light therapy","2023-06-15",{"date":79,"type":45},"2023-06-18",{"date":81,"type":45},"2022-01-12",{"date":83,"type":22},"2029-08",{"name":85,"class":52},"Jessa Hospital"]